Dr. José Miguel Trevejo is a physician-scientist and biotechnology executive who is currently the Chief Medical Officer at Enveda, a biotechnology company that identifies new medicines from nature’s chemistry using AI. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology therapy. Dr. Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, he held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his MD and PhD at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD/PhD Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.
